AnHorn Medicines
Innovation to New Therapeutics - New Opportunities to Target Difficult-to-treat Diseases
12 employees · est. 2020 · Taiwan
Captor Therapeutics SA
Captor Therapeutics aims to treat cancer, infections, and diseases by targeting the difficult-to-drug proteome.
79 employees · est. 2017 · Poland
Captor Therapeutics SA is the older company (2020 vs 2017); Captor Therapeutics SA is the larger of the two.
Side-by-Side Comparison
| Metric | AnHorn Medicines | Captor Therapeutics SA |
|---|---|---|
| Founded | ||
| Founded | 2020 | 2017 older |
| Headquarters | ||
| Headquarters | Taiwan | Poland |
| Employees | ||
| Employees | 12 | 79 larger |
| Industry | ||
| Industry | Health and Wellness | Biopharma, Biotechnology, Pharmaceutical |
| Funding Stage | ||
| Funding Stage | Not tracked yet | IPO |
| Total Funding | ||
| Total Funding | Not tracked yet | $68.50M |
| Funding Rounds | ||
| Funding Rounds | Not tracked yet | 3 |
| Services | ||
| Services | Drug Discovery and Development, AI-Driven Therapeutics, Biopharmaceutical Research | Drug discovery using Targeted Protein Degradation (TPD) technology, Development of therapeutics for cancer and autoimmune diseases, Structure-guided optimization of lead compounds |
| Target Customers | ||
| Target Customers | Healthcare Providers, Pharmaceutical Partners, Patients with Neurological Disorders, Patients with Cancer, Organizations in Prescription Aesthetics | Healthcare providers, Pharmaceutical companies, Patients with severe conditions like cancer and autoimmune diseases, Research institutions |
| Taxonomy | ||
| Taxonomy | Drug Discovery, Targeted Protein Degradation, Bi-functional Ligand Technology, Cancer Therapeutics, Neurodegenerative Disease Treatment, Aging-related Disease Therapy, Protein Degradation Technologies, Disease-related Protein Targeting, BIGPRO Technology, Resistance Overcoming Drugs, Advanced Therapeutics Development, Innovative Drug Pipeline, Proteolysis Targeting, Disease-specific Protein Degradation, Biotech Innovation | Targeted Protein Degradation, Drug Discovery, Cancer Treatment, Autoimmune Disease Treatment, Neurodegenerative Disease Treatment, Proteome Targeting, Biotechnology Innovation, Pharmaceutical Development, Undruggable Proteome, Pharmacokinetics And Pharmacodynamics, Intracellular Protein Degradation, Small Molecule Therapeutics, European Union Co-financed Projects |
| Website | ||
| Website | anhornmed.com | captortherapeutics.com |
About AnHorn Medicines
AnHorn Medicines, established in 2020, is an innovative player in the Health and Wellness industry, headquartered in Taiwan. The company is carving out a niche by focusing on the discovery of new therapeutics aimed at targeting and degrading disease-related proteins. Driven by their proprietary BIG...
About Captor Therapeutics SA
Captor Therapeutics SA is a pioneering company in the Biopharma, Biotechnology, and Pharmaceutical industries, headquartered in Poland. Founded in 2017, the company is publicly listed on the Warsaw Stock Exchange under the ticker WSE:CTX. Captor Therapeutics focuses on advancing drug discovery and...
We will tell you when either one moves
BounceWatch watches AnHorn Medicines and Captor Therapeutics SA for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.
Funding, hiring, leadership and stack changes at AnHorn Medicines and Captor Therapeutics SA — by email.
Frequently Asked Questions
Compare AnHorn Medicines with someone else
Start typing a company name or domain.
Compiled from the BounceWatch company index. We last looked at AnHorn Medicines on 15 Jun 2026, and Captor Therapeutics SA on 15 Jun 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.
